Syndromic testing is a powerful approach that enables the simultaneous detection of multiple pathogens in one single test, saving valuable diagnostic time when compared to traditional testing methods, an attribute that has proved vital during the COVID-19 pandemic.
Here, we’ve pulled together six exclusive articles to boost your understanding of syndromic testing and demonstrate the positive impacts this innovative approach is having on the diagnosis of respiratory infections, CNS inflammation, gastrointestinal pathogens, and more. Plus, learn how the use of syndromic testing panels can promote antimicrobial stewardship and improve resistance.
Our introductory article outlines the fundamental principles and processes of syndromic testing, with a case study example, helping you understand its key benefits. Plus, discover a comprehensive overview of the syndromic panel portfolio offered by BioFire Diagnostics.
In this new age of viral infection, learn more about the pathogenic trends observed during the COVID-19 pandemic and about the important role syndromic testing has played.
Gain insights into why syndromic testing panels are empowering prescribers, identifying potential resistance mechanisms, and aiding antimicrobial stewardship.
Clinicians face diagnostic issues with culture-based testing methods when identifying and treating pneumonia. Discover how syndromic testing could improve antimicrobial stewardship and become the new standard of care.
Efficient diagnosis of gastrointestinal pathogens is not just beneficial for patient treatment, it could also help in the identification of a potential outbreak. Find out how a syndromic testing panel can solve the pitfalls of traditional testing.
The presentation of infections such as meningitis or encephalitis is often nonspecific and can be problematic to diagnose effectively. Find out how syndromic testing can overcome some of these challenges and improve patient management.
*About Emergency Use Authorization:
- This test has not been FDA cleared or approved.
- This test has been authorized by FDA under an EUA for use by authorized laboratories.
- This test has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms.
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner